JP2013518032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518032A5 JP2013518032A5 JP2012533416A JP2012533416A JP2013518032A5 JP 2013518032 A5 JP2013518032 A5 JP 2013518032A5 JP 2012533416 A JP2012533416 A JP 2012533416A JP 2012533416 A JP2012533416 A JP 2012533416A JP 2013518032 A5 JP2013518032 A5 JP 2013518032A5
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- hydrocarbon group
- formula
- anticancer agent
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 24
- 239000002246 antineoplastic agent Substances 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 125000001931 aliphatic group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 3
- 229960001467 bortezomib Drugs 0.000 claims 3
- 229960004562 carboplatin Drugs 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229960004528 vincristine Drugs 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- KOBUOXDVUDRKJX-UHFFFAOYSA-N ethyl 6-[(2-chloro-4-fluorophenyl)methylsulfonyl]cyclohexene-1-carboxylate Chemical compound CCOC(=O)C1=CCCCC1S(=O)(=O)CC1=CC=C(F)C=C1Cl KOBUOXDVUDRKJX-UHFFFAOYSA-N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 206010040021 Sensory abnormalities Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- LRJFAKQFYIWRQN-CYBMUJFWSA-N ethyl (3s)-3-[(2-chloro-4-fluorophenyl)sulfamoyl]-3,6-dihydro-2h-pyran-4-carboxylate Chemical compound CCOC(=O)C1=CCOC[C@H]1S(=O)(=O)NC1=CC=C(F)C=C1Cl LRJFAKQFYIWRQN-CYBMUJFWSA-N 0.000 claims 1
- LEEIJTHMHDMWLJ-CQSZACIVSA-N ethyl (6r)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate Chemical compound CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC1=CC=C(F)C=C1Cl LEEIJTHMHDMWLJ-CQSZACIVSA-N 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012533416A JP6131046B2 (ja) | 2010-01-27 | 2011-01-26 | 抗癌剤により誘発される末梢神経障害を抑制する化合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010015935 | 2010-01-27 | ||
| JP2010015935 | 2010-01-27 | ||
| PCT/JP2011/052077 WO2011093512A1 (en) | 2010-01-27 | 2011-01-26 | Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent |
| JP2012533416A JP6131046B2 (ja) | 2010-01-27 | 2011-01-26 | 抗癌剤により誘発される末梢神経障害を抑制する化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016056186A Division JP2016175903A (ja) | 2010-01-27 | 2016-03-18 | 抗癌剤により誘発される末梢神経障害を抑制する化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518032A JP2013518032A (ja) | 2013-05-20 |
| JP2013518032A5 true JP2013518032A5 (enExample) | 2014-02-13 |
| JP6131046B2 JP6131046B2 (ja) | 2017-05-17 |
Family
ID=43770309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533416A Active JP6131046B2 (ja) | 2010-01-27 | 2011-01-26 | 抗癌剤により誘発される末梢神経障害を抑制する化合物 |
| JP2016056186A Pending JP2016175903A (ja) | 2010-01-27 | 2016-03-18 | 抗癌剤により誘発される末梢神経障害を抑制する化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016056186A Pending JP2016175903A (ja) | 2010-01-27 | 2016-03-18 | 抗癌剤により誘発される末梢神経障害を抑制する化合物 |
Country Status (41)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201406942SA (en) | 2012-04-27 | 2014-11-27 | Nippon Zoki Pharmaceutical Co | Trans-2-decenoic acid derivative and drug containing same |
| SG10202002334PA (en) * | 2013-12-17 | 2020-05-28 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| UY36675A (es) | 2015-05-08 | 2016-12-30 | Takeda Pharmaceuticals Co | Compuestos cíclicos que tienen una acción inhibidora de la señalización del receptor de tipo toll 4 (tlr4) |
| CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| CN109923101B (zh) * | 2016-09-09 | 2021-03-09 | 武田药品工业株式会社 | 环状化合物 |
| JP7317804B2 (ja) * | 2017-09-07 | 2023-07-31 | シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド | ドセタキセル結合体の医薬組成物及び調製方法 |
| CN111432809B (zh) | 2019-07-22 | 2021-11-30 | 广州英赛特生物技术有限公司 | 二氨基胍衍生物及其饲用组合物在制备兽医用药物中的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| DE3789883T2 (de) | 1986-01-09 | 1994-10-06 | Massachusetts Inst Technology | Nukleare faktoren, die mit der regulierung der transkription assoziiert sind. |
| US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| WO1988005083A1 (en) | 1986-12-24 | 1988-07-14 | Whitehead Institute For Biomedical Research | Method of inducible gene expression |
| WO1989007614A1 (en) | 1988-02-12 | 1989-08-24 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| WO1989008147A1 (en) | 1988-03-01 | 1989-09-08 | Whitehead Institute For Biomedical Research | ACTIVITION OF NF-kB PRECURSOR |
| US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| JP3479532B2 (ja) | 1989-03-31 | 2003-12-15 | ザ・チルドレンズ・メディカル・センター・コーポレーション | エイズの痴呆症、脊髄障害および失明の治療 |
| US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5059712A (en) | 1989-09-13 | 1991-10-22 | Cornell Research Foundation, Inc. | Isolating aminoarginine and use to block nitric oxide formation in body |
| US5158883A (en) | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
| EP0557290A1 (en) | 1990-08-23 | 1993-09-01 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
| WO1992017168A1 (en) | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
| WO1992018112A1 (en) | 1991-04-19 | 1992-10-29 | The Children's Medical Center Corporation | Method of preventing nmda receptor complex-mediated neuronal damage |
| US6071876A (en) | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
| IL122427A0 (en) * | 1995-06-07 | 1998-06-15 | Sugen Inc | Pharmaceutical compositions and methods for inhibition of adaptor protein/tyrosine kinase interactions |
| US20020086368A1 (en) | 1997-10-17 | 2002-07-04 | Genentech Inc | Human toll homologues |
| US20020052019A1 (en) | 1997-11-13 | 2002-05-02 | Genentech Inc | Human toll homologue |
| US20030032090A1 (en) | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
| EP1650219B1 (en) | 1997-10-17 | 2007-12-19 | Genentech, Inc. | Human toll homologues |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US20080275104A1 (en) | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| CA2311642A1 (en) | 1997-11-25 | 1999-06-03 | Princeton University | Method for preparing adenovirus vectors, vectors so prepared, and uses thereof |
| US20040072138A1 (en) | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
| DE69923300T2 (de) | 1998-03-09 | 2006-01-05 | Takeda Pharmaceutical Co. Ltd. | Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung |
| KR100778256B1 (ko) | 1999-08-06 | 2007-11-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 치환 방향환 화합물, 그의 제조법 및 용도 |
| SE9903930D0 (sv) * | 1999-10-29 | 1999-10-29 | Astra Pharma Inc | Novel compounds and a novel process for their preparation |
| CA2400804C (en) | 2000-02-04 | 2009-09-01 | Takeda Chemical Industries, Ltd. | Stable emulsion compositions of cycloalkene derivatives |
| HUP0302240A2 (hu) | 2000-05-25 | 2003-10-28 | Schering Corp. | Humán receptorfehérjék, ezekkel kapcsolatos reagensek és eljárások |
| AU2001278705A1 (en) | 2000-08-10 | 2002-02-25 | Takeda Chemical Industries Ltd. | Pharmaceutical composition |
| US6982344B2 (en) | 2000-10-18 | 2006-01-03 | Takeda Pharmaceutical Company Limited | Process for preparation of optically active sulfonamides and intermediates for their synthesis |
| CA2398613C (en) | 2000-11-30 | 2006-09-12 | Tokuyama Corporation | Substrate and production method therefor |
| US20040063685A1 (en) | 2000-12-08 | 2004-04-01 | Juji Ilzawa | Combination Drugs |
| JP5137289B2 (ja) | 2001-08-03 | 2013-02-06 | 武田薬品工業株式会社 | 安定な乳化組成物 |
| EP1495756A4 (en) * | 2002-04-08 | 2009-10-28 | Takeda Pharmaceutical | THERAPEUTIC AGENT FOR SEVERE SEPTIC STATE PREVENTION |
| US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| WO2004074435A2 (en) | 2003-01-30 | 2004-09-02 | Emory University | Methods for identifying and administering agents that bias the immune response via dendritic cells |
| US7485432B2 (en) | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
| US20040191833A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
| WO2005029037A2 (en) | 2003-09-17 | 2005-03-31 | 3M Innovative Properties Company | Selective modulation of tlr gene expression |
| WO2005062854A2 (en) | 2003-12-19 | 2005-07-14 | University Of Cincinnati | Polyamides for nucleic acid delivery |
| MY147790A (en) | 2005-04-28 | 2013-01-31 | Takeda Pharmaceutical | Stable emulsion composition |
| AU2006253356B2 (en) | 2005-06-03 | 2011-12-01 | Ono Pharmaceutical Co., Ltd. | Agent for regeneration and/or protection of nerves |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| WO2007091790A1 (en) | 2006-02-07 | 2007-08-16 | Korea Institute Of Radiological & Medical Sciences | A composition for treating damage of central or peripheral nerve system |
| WO2007100650A2 (en) | 2006-02-23 | 2007-09-07 | Yale University | Drug resistance to plant alkaloids based upon myd88 status in a cell and methods of inhibiting signaling through the tlr-4:myd88 pathway |
| US7943588B2 (en) | 2006-03-28 | 2011-05-17 | Trustees Of Dartmouth College | Method for preventing or treating neuropathic pain |
| JP4962982B2 (ja) | 2006-03-30 | 2012-06-27 | 国立大学法人広島大学 | スクリーニング方法 |
| US20090062355A1 (en) | 2006-04-20 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Pharmaceutical Product |
| EP2018855A1 (en) | 2006-05-15 | 2009-01-28 | Takeda Pharmaceutical Company Limited | Pharmaceutical agent |
| WO2008004673A1 (fr) | 2006-07-07 | 2008-01-10 | Takeda Pharmaceutical Company Limited | Dérives de cycloalkène, procédé de production des dérivés et utilisation de ceux-ci |
| EP1882687A1 (en) * | 2006-07-27 | 2008-01-30 | Amorepacific Corporation | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same |
| WO2008112887A1 (en) | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
| US20100239523A1 (en) | 2007-10-30 | 2010-09-23 | The Regents Of The University Of Colorado | Tlr modulators and methods for using the same |
| JP2011513483A (ja) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
| JP5238381B2 (ja) | 2008-07-07 | 2013-07-17 | スタンレー電気株式会社 | 照明用車両用灯具 |
| US8642614B2 (en) | 2009-09-23 | 2014-02-04 | The Regents Of The University Of Colorado, A Body Corporate | Toll-like receptor modulators and uses thereof |
-
2011
- 2011-01-26 NZ NZ601635A patent/NZ601635A/xx not_active IP Right Cessation
- 2011-01-26 SG SG10201503402XA patent/SG10201503402XA/en unknown
- 2011-01-26 AU AU2011211294A patent/AU2011211294B2/en not_active Ceased
- 2011-01-26 UA UAA201210137A patent/UA109540C2/uk unknown
- 2011-01-26 AR ARP110100247A patent/AR080024A1/es unknown
- 2011-01-26 MY MYPI2012003414A patent/MY163936A/en unknown
- 2011-01-26 BR BR112012018434A patent/BR112012018434A2/pt not_active IP Right Cessation
- 2011-01-26 SG SG2012051967A patent/SG182522A1/en unknown
- 2011-01-26 CN CN201180015681.3A patent/CN102821763B/zh not_active Expired - Fee Related
- 2011-01-26 ES ES11705047.6T patent/ES2560215T3/es active Active
- 2011-01-26 DK DK11705047.6T patent/DK2528598T3/en active
- 2011-01-26 PE PE2012001062A patent/PE20121694A1/es not_active Application Discontinuation
- 2011-01-26 EA EA201290697A patent/EA201290697A1/ru unknown
- 2011-01-26 PT PT117050476T patent/PT2528598E/pt unknown
- 2011-01-26 PH PH1/2012/501538A patent/PH12012501538A1/en unknown
- 2011-01-26 MA MA35162A patent/MA34014B1/fr unknown
- 2011-01-26 ME MEP-2016-31A patent/ME02364B/me unknown
- 2011-01-26 EP EP11705047.6A patent/EP2528598B1/en active Active
- 2011-01-26 UY UY0001033203A patent/UY33203A/es not_active Application Discontinuation
- 2011-01-26 TW TW100102774A patent/TWI481401B/zh not_active IP Right Cessation
- 2011-01-26 HU HUE11705047A patent/HUE027310T2/en unknown
- 2011-01-26 KR KR1020127021846A patent/KR20120118044A/ko not_active Abandoned
- 2011-01-26 RS RS20160076A patent/RS54591B1/sr unknown
- 2011-01-26 CN CN201510072433.2A patent/CN104744321A/zh active Pending
- 2011-01-26 JP JP2012533416A patent/JP6131046B2/ja active Active
- 2011-01-26 HR HRP20160165TT patent/HRP20160165T1/hr unknown
- 2011-01-26 PL PL11705047T patent/PL2528598T3/pl unknown
- 2011-01-26 CA CA2788150A patent/CA2788150C/en not_active Expired - Fee Related
- 2011-01-26 WO PCT/JP2011/052077 patent/WO2011093512A1/en not_active Ceased
- 2011-01-26 SI SI201130755T patent/SI2528598T1/sl unknown
- 2011-01-26 GE GEAP201112845A patent/GEP20166441B/en unknown
- 2011-01-26 MX MX2012008514A patent/MX2012008514A/es not_active Application Discontinuation
- 2011-01-26 US US13/574,848 patent/US20130046000A1/en not_active Abandoned
-
2012
- 2012-07-17 TN TNP2012000364A patent/TN2012000364A1/en unknown
- 2012-07-23 IL IL221066A patent/IL221066A/en not_active IP Right Cessation
- 2012-07-25 DO DO2012000209A patent/DOP2012000209A/es unknown
- 2012-07-26 CL CL2012002079A patent/CL2012002079A1/es unknown
- 2012-07-27 ZA ZA2012/05681A patent/ZA201205681B/en unknown
- 2012-08-07 CR CR20120412A patent/CR20120412A/es unknown
- 2012-08-17 CO CO12140288A patent/CO6592110A2/es not_active Application Discontinuation
- 2012-08-27 EC ECSP12012126 patent/ECSP12012126A/es unknown
-
2013
- 2013-08-20 US US13/971,159 patent/US8901171B2/en not_active Expired - Fee Related
-
2014
- 2014-10-28 US US14/525,576 patent/US20150051256A1/en not_active Abandoned
-
2015
- 2015-04-02 US US14/676,947 patent/US20150203464A1/en not_active Abandoned
-
2016
- 2016-02-19 US US15/047,965 patent/US20160166526A1/en not_active Abandoned
- 2016-03-04 CY CY20161100189T patent/CY1117268T1/el unknown
- 2016-03-18 JP JP2016056186A patent/JP2016175903A/ja active Pending
- 2016-04-12 SM SM201600103T patent/SMT201600103B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503797A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| IN2014DN07283A (enExample) | ||
| JP2015524457A5 (enExample) | ||
| JP2019513770A5 (enExample) | ||
| JP2014524441A5 (enExample) | ||
| CA2569850A1 (en) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer | |
| JP2017511321A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| JP2009514881A5 (enExample) | ||
| JP2011037841A5 (enExample) | ||
| JP2013505946A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2013508288A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| RU2012155118A (ru) | Способы лечения биполярного расстройства | |
| JP2014511366A5 (enExample) | ||
| RU2012109554A (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| JP2007500734A5 (enExample) | ||
| JP2013063968A5 (enExample) | ||
| JP2010500962A5 (enExample) | ||
| JP2017510660A5 (enExample) |